SELLAS Life Sciences posts $10.1M Q3 loss as pivotal leukemia trial results approach

Poin penting

• Biopharmaceutical firm SELLAS Life Sciences reported a third-quarter financial loss of $10.1 million as it prepares to release pivotal trial results for its leukemia treatment.
• The significant net loss highlights the high financial stakes surrounding the company's ongoing clinical trials, which could ultimately influence its future funding opportunities and broader strategic direction going forward.

Diringkas otomatis oleh Kryptokite dari laporan Crypto Briefing. Baca sumber aslinya untuk detail lengkap. Untuk saat ini berita dan ringkasan masih dalam bahasa Inggris.